-
Mashup Score: 0Vantage Surgical Solutions acquires Ophthalmic Surgical Solutions (OSS) - 11 month(s) ago
The Kansas-based company specializes in ophthalmic surgical equipment and services.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 0Novel approaches to treating severe ocular surface and corneal damage - 11 month(s) ago
Severe ocular surface and corneal damage an unseen public health burden.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Novel approaches to treating severe ocular surface and corneal damage. A healthy cornea is vital for clear vision but if the cornea becomes damaged or diseased, it can significantly impact quality of life. Read More: https://t.co/Dl4Y5c0EmD https://t.co/CqUuW52RbX
-
-
Mashup Score: 0WVU suture workshop offers crucial introductory ophthalmic training to medical students - 11 month(s) ago
The skills highlighted during the session are some of the most important tools in an ophthalmologist’s toolbelt and learning and practicing them early, even as a medical student, is crucial.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
The West Virginia University Department of Ophthalmology and Visual Sciences recently hosted a training workshop to hone the skills needed to perform delicate ophthalmic procedures. Read More: https://t.co/Tbsi42jbrp https://t.co/wW0MUKHU9j
-
-
Mashup Score: 2Akari Therapeutics provides update on long-acting PAS-nomacopan candidates for treatment of geographic atrophy - 11 month(s) ago
The company has completed evaluation on candidates and selected a single drug candidate to move forward into clinical trials.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Akari Therapeutics announced it has completed evaluation on long-acting PAS-nomacopan candidates and has selected a version the company plans to take into clinical trials for the treatment of geographic atrophy (GA). Read More: https://t.co/nXCXEvm2DG https://t.co/LrKvkVh1NJ
-
-
Mashup Score: 0SpyGlass Pharma completes $90 Million Series C financing to advance novel treatments for glaucoma and other chronic ophthalmic diseases - 11 month(s) ago
According to the company, the financing will advance novel treatments for glaucoma and other chronic ophthalmic diseases by supporting multiple US clinical trials of its drug delivery platform.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
SpyGlass Pharma announced closing $90 million in Series C financing to help support clinical trials of its drug delivery system in the United States. Read More: https://t.co/sIjFmnEis0 https://t.co/O6AsiZe1Si
-
-
Mashup Score: 1Association between visual functioning and death in AMD - 11 month(s) ago
Researchers investigated the relationship between visual functioning measured using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of AMD.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
In an observational cohort study, researchers investigated the relationship between visual functioning measured using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of AMD Read More: https://t.co/TKbD4YnyS3 https://t.co/AopJ1e7Te9
-
-
Mashup Score: 0Astellas, 4DMT sign agreement for use of 4DMT’s proprietary intravitreal R100 vector for rare ophthalmic targets - 11 month(s) ago
According to the companies, R100 is an adeno-associated virus (AAV) vector invented by 4DMT for intravitreal delivery. It has the ability to penetrate the internal limiting membrane barrier and to efficiently transduce the entire retina, resulting in robust transgene expression within retinal cells.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Astellas Pharma Inc. announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100* vector invented by 4DMT for 1 genetic target implicated in rare monogenic ophthalmic diseases. Read More: https://t.co/Ygc77dRUDs @AstellasUS https://t.co/RAxAEBJHQv
-
-
Mashup Score: 0AAO forms new membership group to support allied health professionals - 11 month(s) ago
American Academy of Ophthalmic Professionals members will enjoy expanded opportunities for career advancement and access to the most up-to-date information in the field, including a new technician learning track at the Academy’s annual meeting in San Francisco this November.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
In an effort to support the professional interests of allied health professionals, the American Academy of Ophthalmology has established a new membership group to welcome in members of the Association of Technical Personnel in Ophthalmology. Read More: https://t.co/HIpNwr7vj6 https://t.co/K8LhAsDqpX
-
-
Mashup Score: 0Novel approaches to treating severe ocular surface and corneal damage - 11 month(s) ago
Severe ocular surface and corneal damage an unseen public health burden.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Novel approaches to treating severe ocular surface and corneal damage. A healthy cornea is vital for clear vision but if the cornea becomes damaged or diseased, it can significantly impact quality of life. Read More: https://t.co/Dl4Y5c1ccb https://t.co/fTEIXrEUIa
-
-
Mashup Score: 0Viridian announces positive data from ongoing Phase 1/2 trial evaluating VRDN-001 in patients diagnosed with chronic TED - 11 month(s) ago
According to the company, VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001 10 mg/kg or 3 mg/kg.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Viridian Therapeutics announced positive preliminary data from its ongoing Phase 1/2 clinical trial of VRDN-001 an investigational full antagonist antibody to the insulin-like growth factor 1 receptor in patients with chronic thyroid eye disease Read More:https://t.co/r89LNl7FEe https://t.co/llTCCvRtVV
-
Vantage Surgical Solutions has announced the acquisition of Ophthalmic Surgical Solutions (OSS), a Kansas-based company specializing in ophthalmic surgical equipment and services. Read More: https://t.co/HkIJpiEmBK https://t.co/6LEBLFJZGV